Radiation precautions for inpatient and outpatient (177)Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours

BACKGROUND: (177)Lu-DOTATATE peptide receptor radionuclide therapy is administered to patients on an inpatient and outpatient basis for the treatment of well-differentiated, metastatic neuroendocrine tumours. Following administration, these patients present an external radiation hazard due to the ga...

Descripción completa

Detalles Bibliográficos
Autores principales: Levart, D., Kalogianni, E., Corcoran, B., Mulholland, N., Vivian, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484059/
https://www.ncbi.nlm.nih.gov/pubmed/31025215
http://dx.doi.org/10.1186/s40658-019-0243-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484059/
https://www.ncbi.nlm.nih.gov/pubmed/31025215
http://dx.doi.org/10.1186/s40658-019-0243-1

Ejemplares similares